126 related articles for article (PubMed ID: 34923575)
21. Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery.
Lim H; In Shim J; Park SJ; Noh J; Kim TM; Lee M; Choi CH; Chung HH; Kim TJ; Lee JW; Kim JW; Kim BG; Park NH; Song YS; Kim SY; Park SY; Kim HS; Lee YY
Gynecol Oncol; 2022 Jun; 165(3):493-499. PubMed ID: 35367074
[TBL] [Abstract][Full Text] [Related]
22. Radiomics Analysis of PET and CT Components of
Wang X; Lu Z
Front Oncol; 2021; 11():638124. PubMed ID: 33928029
[TBL] [Abstract][Full Text] [Related]
23. [Prediction of platinum-based chemotherapy sensitivity for epithelial ovarian cancer by multi-sequence MRI-based radiomic nomogram].
Mao MM; Li HM; Shi J; Qiu QS; Feng F
Zhonghua Yi Xue Za Zhi; 2022 Jan; 102(3):201-208. PubMed ID: 35042289
[No Abstract] [Full Text] [Related]
24. The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer.
Bogani G; Leone Roberti Maggiore U; Paolini B; Diito A; Martinelli F; Lorusso D; Raspagliesi F
J Gynecol Oncol; 2019 Jan; 30(1):e4. PubMed ID: 30479088
[TBL] [Abstract][Full Text] [Related]
25. Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer.
Risum S; Loft A; Høgdall C; Berthelsen AK; Høgdall E; Lundvall L; Nedergaard L; Engelholm SA
Acta Oncol; 2011 Apr; 50(3):415-9. PubMed ID: 20698810
[TBL] [Abstract][Full Text] [Related]
26. Prognostic implication of the metastatic lesion-to-ovarian cancer standardised uptake value ratio in advanced serous epithelial ovarian cancer.
Chung HH; Lee M; Kim HS; Kim JW; Park NH; Song YS; Cheon GJ
Eur Radiol; 2017 Nov; 27(11):4510-4515. PubMed ID: 28593431
[TBL] [Abstract][Full Text] [Related]
27. Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery.
Hosono S; Kajiyama H; Mizuno K; Sakakibara K; Matsuzawa K; Takeda A; Kawai M; Nagasaka T; Kikkawa F
Int J Clin Oncol; 2011 Oct; 16(5):524-32. PubMed ID: 21431342
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
[TBL] [Abstract][Full Text] [Related]
29. A CT-based radiomics nomogram for predicting early recurrence in patients with high-grade serous ovarian cancer.
Chen HZ; Wang XR; Zhao FM; Chen XJ; Li XS; Ning G; Guo YK
Eur J Radiol; 2021 Dec; 145():110018. PubMed ID: 34773830
[TBL] [Abstract][Full Text] [Related]
30. Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
Keunecke C; Kulbe H; Dreher F; Taube ET; Chekerov R; Horst D; Hummel M; Kessler T; Pietzner K; Kassuhn W; Heitz F; Muallem MZ; Lang SM; Vergote I; Dorigo O; Lammert H; du Bois A; Angelotti T; Fotopoulou C; Sehouli J; Braicu EI
Gynecol Oncol; 2022 Aug; 166(2):334-343. PubMed ID: 35738917
[TBL] [Abstract][Full Text] [Related]
31. Predictive Relevance of Circulating miR-622 in Patients with Newly Diagnosed and Recurrent High-Grade Serous Ovarian Carcinoma.
Vigneron N; Vernon M; Meryet-Figuière M; Lambert B; Briand M; Louis MH; Krieger S; Joly F; Lheureux S; Blanc-Fournier C; Gauduchon P; Poulain L; Denoyelle C
Clin Chem; 2020 Feb; 66(2):352-362. PubMed ID: 32040573
[TBL] [Abstract][Full Text] [Related]
32. Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.
Wang C; Armasu SM; Kalli KR; Maurer MJ; Heinzen EP; Keeney GL; Cliby WA; Oberg AL; Kaufmann SH; Goode EL
Clin Cancer Res; 2017 Aug; 23(15):4077-4085. PubMed ID: 28280090
[No Abstract] [Full Text] [Related]
33. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
34. Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: A machine learning, multicenter study.
Yu Y; He Z; Ouyang J; Tan Y; Chen Y; Gu Y; Mao L; Ren W; Wang J; Lin L; Wu Z; Liu J; Ou Q; Hu Q; Li A; Chen K; Li C; Lu N; Li X; Su F; Liu Q; Xie C; Yao H
EBioMedicine; 2021 Jul; 69():103460. PubMed ID: 34233259
[TBL] [Abstract][Full Text] [Related]
35. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
[TBL] [Abstract][Full Text] [Related]
36. Development of survival predictors for high-grade serous ovarian cancer based on stable radiomic features from computed tomography images.
Hu J; Wang Z; Zuo R; Zheng C; Lu B; Cheng X; Lu W; Zhao C; Liu P; Lu Y
iScience; 2022 Jul; 25(7):104628. PubMed ID: 35800777
[TBL] [Abstract][Full Text] [Related]
37. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract][Full Text] [Related]
38. Development of a radiomic-clinical nomogram for prediction of survival in patients with serous ovarian cancer.
Hong Y; Liu Z; Lin D; Peng J; Yuan Q; Zeng Y; Wang X; Luo C
Clin Radiol; 2022 May; 77(5):352-359. PubMed ID: 35264303
[TBL] [Abstract][Full Text] [Related]
39. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
40. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
